-
Beyond the Congress Video Edits Sonali Smith_recap_#BeyondASH21recap
2:41
-
Beyond the Congress Video Edits Nitin Jain_recap_#BeyondASH21recap
3:07
-
Ciara Freeman, MBBCH, BAO, MSc, FRCPC, FRCPathUK; John Gribben, DSc, FRCP, FRCPath #HemeWorkshop2020
8:50
Ciara Freeman talks to John Gribben about how treatment strategies can affect future treatment decisions, specifically how early treatments can influence T cell health and potential efficacy of CAR T cell therapy.
-
Mitchell Smith, MD, PhD; GW Cancer Center; 5Live #ASH20
5:20
Key insights from the 2020 Annual Hematology meeting in Lymphoma
-
Loretta Nastoupil, MD; University of Texas MD Anderson Cancer Center; 5Live #ASH20
7:43
Key insights from the 2020 Annual Hematology meeting in Lymphoma
-
Julie Vose, MD, MBA, FASCO; University of Nebraska Medical Center; 5Live #ASH20
1:54
Key insights from the 2020 Annual Hematology meeting in Lymphoma
-
Paolo Strati, MD; University of Texas MD Anderson Cancer Center 5Live #ASCO20
5:45
Key insights on Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).
-
Nirav Niranjan Shah, MD, MS Medical College of Wisconsin 5Live #ASCO20
4:51
Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
-
Hun Ju Lee, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO2020
5:08
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
-
Constantine Si Lun Tam, MBBS, MD Peter MacCallum Cancer Centre University of Melbourne 5Live #ASCO20
1:43
Key Insights on Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib
-
Constantine Si Lun Tam, MBBS, MD Peter MacCallum Cancer Centre University of Melbourne 5Live #ASCO20
5:54
"Key Insights on ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM) "
- Next Page